Professional
Added to YB: 2024-02-22
Pitch date: 2024-01-18
VRTX [bullish]
Vertex Pharmaceuticals Incorporated
+4.27%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Market Cap
$108.3B
Pitch Price
$433.52
Price Target
N/A
Dividend
N/A
EV/EBITDA
20.02
P/E
30.01
EV/Sales
8.37
Sector
Biotechnology
Category
growth
Show full summary:
Harding Loevner Portfolio Holding - Vertex Pharmaceuticals
$VRTX: CF dominance w/ Trikafta, 1st CRISPR gene-editing therapy Casgevy approved for sickle cell. Expanding to Type 1 diabetes & non-opioid pain mgmt. Milestones ahead, revenue projections up 2x in '23. Frequent innovation protects share, rivals can't match pace.
Read full article (2 min)